Figure 2From: Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry Cost-utility planes of 1000 bootstrap replicates of the incremental cost and quality-adjusted life years gained by the treat-to-target strategy versus usual care in early rheumatoid arthritis after A) two and B) three years of follow-up. Back to article page